The Japanese arm of US-based healthcare firm Schering-Plough has received marketing approval for Nasonex (mometasone furoate monohydrate) Nasal Spray 50mcg for the treatment of allergic rhinitis in adult patients.

Nasonex is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day.  Nasonex is the first intranasal steroid to be approved in Japan for once-daily administration. Nasonex is currently approved in over 100 countries worldwide and is anticipated to be available in Japan this fall.

Dr Robert J Spiegel, chief medical officer and senior vice president, Schering-Plough Research Institute, said allergies are a growing health problem in Japan. Nasonex provides physicians with an important treatment option for the relief of nasal allergy symptoms, especially for those patients looking for the convenience of a once-daily treatment.

Allergic rhinitis, which encompasses the outdoor symptoms of seasonal allergic rhinitis (SAR) and the indoor symptoms of perennial allergic rhinitis (PAR), affects an estimated 18 to 23 million people in Japan. Nasal allergy symptoms classically include sneezing, nasal itching, nasal discharge and congestion. Japan is the world’s second largest market for prescription and over-the-counter medications for the treatment of allergies.